News

European equities traded in the US as American depositary receipts were tracking sharply lower late

AMGN stands out compared to Biogen given its broader product portfolio, pipeline depth and steadier growth outlook despite patent and competition risks.

Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market.

With an annual dividend yield of 3.75%, Novo Nordisk A/S (NYSE:NVO) is included among the 12 Best NYSE Stocks to Buy for Dividends. Novo Nordisk A/S (NYSE:NVO) is a leading global healthcare company, founded in 1923 and headquartered in Denmark. On June 19, Nordea upgraded Novo Nordisk A/S (NYSE:NVO) from ‘Hold’ to ‘Buy’ and assigned the […]

Novo Nordisk has entered into an outsourcing agreement with Shantha Biologics for cartridge fill-finish manufacturing services in India. The partnership expands Novo Nordisk’s production footprint into a key pharmaceutical manufacturing hub. The deal is intended to support the company’s global supply chain and its ability to meet demand for cartridge-based products. Novo Nordisk, traded as CPSE:NOVO B, is making this move while its share price stands at DKK314.6. The stock is up 2.2% over...

Medicare is launching a temporary program that will cover Novo’s Wegovy injection and tablets, as well as Lilly’s Zepbound KwikPen formulation and its Foundayo tablets.

Roche won FDA priority review for Enspryng in thyroid eye disease, with a decision date in October and phase III data backing the filing.

LLY is expanding its revenue base beyond Mounjaro and Zepbound with new launches and label expansions that can strengthen long-term growth.

Artificial intelligence is reshaping nearly every industry, but some of its biggest opportunities are emerging far from Silicon Valley. Biotechnology has spent decades producing breakthrough medicines, yet drug development has remained painfully slow, often taking 10 to 15 years while roughly 90% of candidates never reach approval. AI is beginning to change that equation. By ... AI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunity

NVO and VKTX stocks offer contrasting opportunities in the fast-growing obesity market, with key differences in growth, risk and pipeline strength.

LLY hit a record high after a positive EU panel opinion for Jaypirca and expanded $50/month Medicare access for Zepbound and Foundayo.

Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.

The red-hot market has plenty of room for additional therapies from big name players and clinical stage companies alike.

Novo Nordisk A/S (NYSE:NVO) is one of the best low volatility stocks to buy under $50. Novo Nordisk A/S (NYSE:NVO) announced on June 11 that the Wegovy® pill has been approved in the UK as an adjunct to a reduced-calorie diet and increased physical activity, offering a first-of-its-kind alternative to injectable treatments for adults. The […]

Earnings are coming up for Nike as the company tries to engineer a turnaround, but Nike stock continues to plumb 52-week lows.

Hims had 2.6 million subscribers in Q1, up 9% year over year, with Q2 expected to show how much the Novo deal is helping demand.

Novo Nordisk (CPSE:NOVO B) received UK approval for an oral version of Wegovy, the first authorized daily GLP-1 pill for weight management. The authorization covers obesity and overweight adults, offering an alternative to injectable GLP-1 therapies. The decision is expected to influence how obesity is treated in primary care and specialist settings across the UK. Retailers and consumer companies are already tracking GLP-1 use as they assess shifts in spending on food, fitness, and wellness...

Novo Nordisk is no longer the front-runner, but it's not out of the running, either.

Viking Therapeutics jumps after it starts its first human study of VK3019, expanding its obesity pipeline with a second candidate alongside its lead program, VK2735.

Shell, Novo, SAP, Rave and Vaso are included in this Analyst Blog.

These companies' innovative qualities could help them get ahead of their peers in capitalizing on AI.

Retail traders cited Novo CEO Mike Doustdar’s comment that Novo could afford a $20B, $30B or $40B deal if it was “worth it.”

Shell, Novo Nordisk and SAP headline Zacks' top research reports, highlighting growth drivers, guidance outlooks and key risks shaping performance.

We recently compiled a list of the 10 Best Weight Loss Drug Stocks to Buy in 2026. Hims & Hers Health, Inc. (NYSE:HIMS) is one of the best weight loss drugs on this list. TheFly reported on June 17 that Barclays maintained its Overweight rating on HIMS while increasing its price target to $39.00 from $29.00. The […]

We recently compiled a list of the 10 Best Weight Loss Drug Stocks to Buy in 2026. Novo Nordisk A/S (NYSE:NVO) is one of the best weight loss drugs on this list. TheFly reported on June 16 that Berenberg increased its price target for NVO shares to DKK 325 from DKK 300 while maintaining its Buy rating […]

Lilly's GLP-1 leadership, expanding pipeline and strong earnings growth outlook make it a standout pick over Pfizer despite its premium valuation.

Whether from layoffs or exits, Novo Nordisk, Genentech and Allogene saw changes to their executive teams over the past few months.

The rally reflects broader positive sentiment toward Viking’s lead candidate, VK2735, a dual GLP-1/GIP receptor agonist being developed in both injectable and oral forms for obesity.

Novo Nordisk A/S (NYSE:NVO) is among the Best Pharmaceutical Stocks. On June 19, Novo Nordisk A/S (NYSE:NVO)’s primary owner, the Novo Nordisk Foundation, reported that it is launching research incubators across Europe to speed up obesity and diabetes drug development. The foundation said it is funding a pan-European program targeting cardiometabolic diseases. It will commit up […]

Everyone is still arguing about Novo Nordisk (NYSE:NVO), the Danish obesity juggernaut whose GLP-1 franchise turned Wegovy and Ozempic into household names and dragged the entire pharma sector into a multi-year hype cycle. But here’s what you should actually be watching. The reality check has already started, and the numbers are uglier than the headlines ... Forget Novo Nordisk. Pfizer’s Obesity Pipeline Is Coming, and It Pays You 6.8% While You Wait